11
Views
11
CrossRef citations to date
0
Altmetric
Rapid communication

Evidence for common binding of acetaminophen and bromobenzene to the 58‐kda acetaminophen‐binding protein

, &
Pages 263-269 | Received 03 Aug 1995, Accepted 07 Aug 1995, Published online: 20 Oct 2009
 

Abstract

Acetaminophen (APAP) toxicity has been closely associated with covalent binding to a cytosolic protein of approximately 58 kDa (58‐ABP). To determine if metabolites of other toxicants might also selectively target this protein, studies were conducted with bromobenzene (BrB). Mice were given phenobarbital (80 mg/kg/d × 4 d) and were killed 4 h after challenge with 800 mg BrB/kg. Liver cytosols from BrB‐treated or naive mice were incubated with an APAP activating system. Cytosolic fractions were analyzed for APAP binding by Western blotting with anti‐APAP antibody. Binding to 58‐ABP was selectively decreased in liver cytosol from BrB‐treated mice while binding to other targets was minimally affected. Western blotting of the same samples with anti‐58‐ABP antisera showed that this decrease in binding did not result from diminished 58‐ABP content. HPLC analysis of APAP‐N‐acetyl cysteine conjugate formation in vitro indicates that APAP activation was not altered in the incubates with cytosol from BrB‐treated mice. These results suggest that the 58‐ABP may be a common target for electrophiles in reactive intermediate toxicity.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.